Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.54 |
| ▸ | MTOR | P42345 | 10/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11029184 | 0.88 | PIK3CA (0.56) | PIK3CAMTORPDE4BPDE4DPDE4C | |
| SCHEMBL11029462 | 0.83 | PIK3CA (0.54) | PIK3CAMTORPDE4BPDE4DPDE4C | |
| SCHEMBL11029742 | 0.82 | PIK3CA (0.70) | PIK3CAMTOR | |
| SCHEMBL11029150 | 0.79 | PIK3CA (0.58) | PIK3CAMTORPDE4BPDE4DPDE4C | |
| SCHEMBL751744 | 0.79 | PIK3CA (0.57) | PIK3CAMTORPDE4BPDE4DPDE4C | |
| SCHEMBL751191 | 0.79 | PIK3CA (0.57) | PIK3CAMTORPDE4BPDE4DPDE4C | |
| SCHEMBL2787401 | 0.78 | PIK3CA (0.52) | PIK3CAMTOR | |
| SCHEMBL2772531 | 0.78 | PIK3CA (0.52) | PIK3CAMTORPDE4BPDE4D | |
| SCHEMBL11029646 | 0.78 | PIK3CA (0.68) | PIK3CAMTOR | |
| SCHEMBL753756 | 0.78 | PIK3CA (0.56) | PIK3CAMTORPDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885PDE4B 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.